Go Pro
→ Major Buy Alert Issued for September 30th (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$8.30
+0.1%		$8.72
$6.97
▼
$14.51
$534.88M1.75769,115 shs639,835 shs
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$8.64
+0.7%		$7.03
$5.16
▼
$9.32
$557.86M1.07534,388 shs314,184 shs
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.01
+0.3%		$4.40
$2.42
▼
$8.51
$130.90M1.8172,892 shs253,528 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.78
-7.1%		$1.67
$1.30
▼
$3.48
$577.44M1.71.48 million shs1.77 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
+0.12%-1.19%-11.32%+1.97%+10.37%
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
+0.70%+7.06%+28.38%+35.21%+44.97%
Oncocyte Corp stock logo
IMDX
Oncocyte
+0.25%-0.25%-7.60%-25.33%+400,999,900.00%
ProKidney Corp. stock logo
PROK
ProKidney
-7.07%-1.93%+10.25%-1.39%-33.77%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$8.30
+0.1%		$8.72
$6.97
▼
$14.51
$534.88M1.75769,115 shs639,835 shs
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
$8.64
+0.7%		$7.03
$5.16
▼
$9.32
$557.86M1.07534,388 shs314,184 shs
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.01
+0.3%		$4.40
$2.42
▼
$8.51
$130.90M1.8172,892 shs253,528 shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.78
-7.1%		$1.67
$1.30
▼
$3.48
$577.44M1.71.48 million shs1.77 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
+0.12%-1.19%-11.32%+1.97%+10.37%
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
+0.70%+7.06%+28.38%+35.21%+44.97%
Oncocyte Corp stock logo
IMDX
Oncocyte
+0.25%-0.25%-7.60%-25.33%+400,999,900.00%
ProKidney Corp. stock logo
PROK
ProKidney
-7.07%-1.93%+10.25%-1.39%-33.77%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.27
Hold$14.1770.68% Upside
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
2.89
Moderate Buy$18.00108.33% Upside
Oncocyte Corp stock logo
IMDX
Oncocyte
2.33
Hold$10.50161.85% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.67
Moderate Buy$12.00576.06% Upside

Current Analyst Ratings Breakdown

Latest IMDX, EPRX, ARVN, and PROK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/18/2026
Oncocyte Corp stock logo
IMDX
Oncocyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
8/13/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D)
8/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$10.00
8/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$14.00
8/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$24.00 ➝ $21.00
8/5/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$11.00 ➝ $12.00
8/5/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/4/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$15.00 ➝ $11.00
8/4/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight
8/4/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$18.00
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$262.60M2.04N/AN/A$6.76 per share1.23
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/A$1.41 per shareN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.05M32.40N/AN/A($1.10) per share-3.65
ProKidney Corp. stock logo
PROK
ProKidney
$890K602.94N/AN/A($3.36) per share-0.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$80.80M$0.1083.01N/AN/A2.94%1.91%1.29%11/4/2026 (Estimated)
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$38.58M-$1.02N/AN/AN/AN/A-63.97%-43.32%11/3/2026 (Estimated)
Oncocyte Corp stock logo
IMDX
Oncocyte
-$50.22M-$1.49N/AN/AN/A-2,955.63%N/A-107.52%N/A
ProKidney Corp. stock logo
PROK
ProKidney
-$68.99M-$0.55N/AN/AN/A-10,288.39%N/A-27.39%11/9/2026 (Estimated)

Latest IMDX, EPRX, ARVN, and PROK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
-$0.25-$0.23+$0.02-$0.23N/AN/A
8/10/2026Q2 2026
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A-$0.23N/A-$0.31N/A$0.24 million
8/10/2026Q2 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14-$0.15-$0.01-$0.15$0.19 million$0.15 million
8/4/2026Q2 2026
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.3741$2.58+$2.9541$2.58$60.71 million$249.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/AN/AN/AN/AN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
7.91
7.91
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
0.02
16.00
16.00
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A
2.00
1.98
ProKidney Corp. stock logo
PROK
ProKidney
N/A
8.36
8.36

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
Oncocyte Corp stock logo
IMDX
Oncocyte
55.35%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
7.30%
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
N/A
Oncocyte Corp stock logo
IMDX
Oncocyte
2.21%
ProKidney Corp. stock logo
PROK
ProKidney
39.83%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
24664.52 million59.81 millionOptionable
Eupraxia Pharmaceuticals Inc. stock logo
EPRX
Eupraxia Pharmaceuticals
4965.02 millionN/AN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
5832.72 million32.00 millionN/A
ProKidney Corp. stock logo
PROK
ProKidney
231302.32 million181.91 millionOptionable

Recent News About These Companies

ProKidney (NASDAQ:PROK) Stock Price Down 7.6% - Should You Sell?
September 21 at 1:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-prokidney-nasdaq-prok-stock-price-down-76-should-you-sell-2026-09-21/
ProKidney (PROK) Stock Forecast & Price Target
September 19 at 9:50 AM  |  investing.comhttps://www.investing.com/equities/prokidney-consensus-estimates
ProKidney (NASDAQ:PROK) Trading 6% Higher - Still a Buy?
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-prokidney-nasdaq-prok-trading-6-higher-still-a-buy-2026-09-16/
ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict
September 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/prokidney-prok-nears-pivotal-kidney-052815909.html
ProKidney (NASDAQ:PROK) Stock Price Up 7.6% - Should You Buy?
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-prokidney-nasdaq-prok-stock-price-up-76-should-you-buy-2026-09-04/
ProKidney Corp. (PROK) Options Chain - Yahoo Finance
August 26, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PROK/options/
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936908-prokidney-do-or-die-phase-3-meets-a-dwindling-balance-sheet-rating-downgrade
ProKidney (PROK) Receives a Hold from Morgan Stanley
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PROK/pressreleases/3803711/prokidney-prok-receives-a-hold-from-morgan-stanley/
ProKidney (PROK) Receives a Hold from Morgan Stanley
August 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PROK/pressreleases/3803711/prokidney-prok-receives-a-hold-from-morgan-stanley/
ProKidney (PROK) Gets a Buy from Guggenheim
August 12, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/PROK/pressreleases/3800782/prokidney-prok-gets-a-buy-from-guggenheim/
ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates
August 10, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972334/prokidney-corp-prok-reports-q2-loss-misses-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2972334
ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights
August 10, 2026  |  manilatimes.netM
ProKidney Cell Therapy Thwarts Onerous Dialysis
July 30, 2026  |  bloomberg.comhttps://www.bloomberg.com/news/audio/2026-07-30/vanguards-of-healthcare-prokidney-aims-to-stave-off-dialysis
ProKidney Corp. (PROK) Latest Stock News & Headlines - Yahoo Finance
July 14, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/PROK/news/
ProKidney Corp (NASDAQ: PROK) - Share Price and Research
July 13, 2026  |  intelligentinvestor.com.auI
What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite?
July 9, 2026  |  kalkinemedia.comK
Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path
June 17, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/why-prokidney-prok-is-building-its-bull-case-around-rilparencels-accelerated-approval-path-1783024/
ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout
June 2, 2026  |  bizjournals.comhttps://www.bizjournals.com/triad/news/2026/06/02/prokidney-ken-locke-chief-technology-officer.html
ProKidney Appoints Kenneth Locke as Chief Technical Officer
June 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/02/3305064/0/en/prokidney-appoints-kenneth-locke-as-chief-technical-officer.html
ProKidney shareholders reaffirm board and auditor at 2026 meeting
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/prokidney-shareholders-reaffirm-board-and-auditor-at-2026-meeting?utm_source=marketbeat.com&utm_medium=referral
ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates
May 15, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2922197/prokidney-corp-prok-reports-q1-loss-tops-revenue-estimates?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_4-2922197

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arvinas stock logo

Arvinas NASDAQ:ARVN

$8.30 +0.01 (+0.12%)
As of 09/21/2026 04:00 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Eupraxia Pharmaceuticals stock logo

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.64 +0.06 (+0.70%)
As of 09/21/2026 04:00 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Oncocyte stock logo

Oncocyte NASDAQ:IMDX

$4.01 +0.01 (+0.25%)
As of 09/21/2026 04:00 PM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

ProKidney stock logo

ProKidney NASDAQ:PROK

$1.78 -0.14 (-7.07%)
As of 09/21/2026 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas